Please be aware that this website relies on the use of cookies to function correctly and involves some cookies being downloaded onto your device. By continuing to use this website, you agree to our use of these cookies. This helps us to improve the content of the website so that it is more useful and relevant to you. For more information please see our Privacy Policy.


Patient Access to Cancer care Excellence

A Global Vision

Faster steps forward: towards cures for cancer and access to best treatment and care for individual patients.

Learn more about PACE

Richard B. Gaynor, MD

Richard B. Gaynor, M.D. joined Eli Lilly and Company as Vice President for Cancer Research and Clinical Investigation in August 2002. Currently, Dr. Gaynor is Vice President, Clinical Development and Medical Affairs at Lilly.

Gaynor received a doctor of medicine degree from the University Of Texas Southwestern Medical School. He served his internship and residency in internal medicine from at Parkland Memorial Hospital in Dallas, Texas. He completed a fellowship in hematology-oncology at the University of California at Los Angeles (UCLA) School of Medicine and then served on the faculty there. He received board certification in internal medicine, hematology and medical oncology.

Prior to joining Lilly, Gaynor was a Professor of Medicine and Microbiology at the University of Texas Southwestern Medical Center (UTSW) in Dallas and held several important leadership positions. He was Chief of the Division of Hematology and Oncology at UTSW and Director of the Harold C. Simmons Comprehensive Cancer Center there in addition to his work as the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology. He served on numerous NIH advisory committees and was elected to both the American Society of Clinical Investigation and Association of American Physicians.

Gaynor is on the editorial board of several scientific journals and has an extensive publication record totaling more than 140 scientific articles. He serves on the board of the Damon Runyon Cancer Research Foundation and the Walther Cancer Institute and on several committees for the American Association of Cancer Research and other leading cancer organizations.